ct103a cells
Idiopathic Inflammatory Myopathies
Tongji HospitalCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the Idiopathic Inflammatory Myopathies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Filgotinib UMC Utrecht | Phase 2 | CCC |
Autologous Cd19-Bcma Dual-Target Car T-Cell Therapy Beijing Boren Hospital | Phase 1 | CC |
hbi0101 cart Polina Stepensky | Phase 1 | CC |
azd0120 AstraZeneca | Phase 1 | CC |
her2bbζ/cd19t+ t cells PersonGen BioTherapeutics (Suzhou) Co., Ltd. | Early Phase 1 | C |
Fludarabine Tongji Hospital | Early Phase 1 | C |
Cyclophosphamide Tongji Hospital | Early Phase 1 | C |
Same molecule, other indications
ct103a cells is also rated in:
myelin oligodendrocyte glycoprotein antibody-associated diseaseDormant
C
Indicative ·
39 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →